.png){kind=icon}
返回
Pomalidomide: First Global Approval
.png){kind=icon}
PRE
AI
DOI：10.1007/s40265-013-0047-x.png)
.png){kind=icon}
原文求助.png){kind=icon}
分享.png){kind=icon}
收藏
摘要
En 中文
Pomalidomide (Pomalyst (R)) is a small molecule analogue of thalidomide under development with Celgene Corporation for the oral treatment of haematological and connective tissue diseases. Pomalidomide has been approved in the USA and is awaiting approval in the EU for use with low-dose dexamethasone for the treatment of relapsed and refractory multiple myeloma that has progressed following at least two prior therapies, including lenalidomide and bortezomib. The efficacy and safety of pomalidomide as monotherapy in patients with relapsed and refractory multiple myeloma has also been evaluated in a phase III trial. The agent is in phase III clinical development for the treatment of myelofibrosis and in phase II development for systemic sclerosis. Pomalidomide is also being investigated in patients with amyloidosis, prostate cancer, small cell lung cancer, pancreatic cancer, graft-versus-host disease, and Waldenstrom's macroglobulinaemia. This article summarizes the milestones in the development of pomalidomide leading to this first global approval for relapsed and refractory multiple myeloma.
Keyword:
IMMUNOMODULATORY DRUGS
MULTIPLE-MYELOMA
PHASE-I
LENALIDOMIDE
THALIDOMIDE
CC-4047
CELLS
EXPRESSION
THERAPY
TRIAL
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
引用论文
分享收藏
Regulation of Nerve Growth Mediated by Inositol 1,4,5-Trisphosphate Receptors in Growth Cones.png)
Science
ScienceIF0
PREAI
分享收藏分享收藏分享收藏
查看更多内容